Comparison of intravitreal bevacizumab, intravitreal triamcinolone acetonide, and macular grid augmentation in refractory diffuse diabetic macular edema: A prospective, randomized study

Oman Journal of Ophthalmology

Volumn 5, Issue 3, 2012, Pages 166-170

  Azad, Rajvardhan ^a   Sain, Siddarth ^a   Sharma, Yog ^a   Mahajan, Deepankur ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Diabetic macular edema; Intravitreal bevacizumab; Intravitreal triamcinolone; laser photocoagulation

Indexed keywords

EID: 84873585103     PISSN: 0974620X     EISSN: 09747842     Source Type: Journal    
DOI: 10.4103/0974-620X.106100     Document Type: Article

References (30)

1. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985;103:1796-806.
2. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1987;94:761-74.
3. Akduman L, Olk RJ. Laser photocoagulation of diabetic macular edema. Ophthalmic Surg Lasers 1997;28:387-408.
4. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse macular oedema: Long-term visual results. Ophthalmology 1991;98:1594-602.
5. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1995;113:1144-55.
6. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003;136:122-35. (Pubitemid 36794505)
7. Bhagat N, Ruben A, Grigorian MD, Tutela A, Zarbin MA. Diabetic Macular Edema: Pathogenesis and Treatment. Surv Ophthal 2009;54:1-33.
8. Sander B, Larsen M, Moldow B, Lund-Andersen H. Diabetic macular edema: Passive and active transport of fluorescein through the bloodretina barrier. Invest Ophthalmol Vis Sci 2001;42:433-8. (Pubitemid 32121476)
9. Chew EY, Ferris FL 3rd, Csaky KG, Murphy RP, Agrón E, Thompson DJ, et al. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: The early treatment diabetic retinopathy follow- up study. Ophthalmology 2003;110:1683-9. (Pubitemid 37025423)
10. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: Preliminary results of a prospective controlled trial. Ophthalmology 2004;111:218-24. (Pubitemid 38183217)
11. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-7. (Pubitemid 34465226)
12. Jonas JB, Kreissig I. Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61. (Pubitemid 36401766)
13. Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136:791-6. (Pubitemid 37330020)
14. Jonas JB, Kreissig I, Degenring R. Secondary chronic open-angle glaucoma after intravitreal triamcinolone acetonide. Arch Ophthalmol 2003;121:729-30. (Pubitemid 36554480)
15. Diabetic Retinopathy Clinical Research Network. A Randomised trial comparing intravitreal triamcinolone acetonide with focal/ grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115: 1447-59.
16. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E Jr. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992;110:1155-9.
17. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25:581-611. (Pubitemid 39099316)
18. Adamis AP0, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111-8. (Pubitemid 40365933)
19. Van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005;293: 1509-13. (Pubitemid 40393297)
20. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreat toxicity of bevacizumab Avastin. Retina 2006;26:257-61. (Pubitemid 44318176)
21. Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262-9. (Pubitemid 44318177)
22. Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 2006;142:162-4. (Pubitemid 43946808)
23. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-9. (Pubitemid 41073113)
24. Scott IU, Edwords AR, Beck RW, Bressler NM, Chan CK, Elman MJ, et al. Diabetic retinopathy clinical research network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-7.
25. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diabetic macular edema. Retina 2006;26:999-1005. (Pubitemid 44973218)
26. Kumar A, Sinha S. Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Indian J Ophthalmol 2007;55:451-5.
27. Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 2008;86:372-6.
28. Kernt M, Neubauer AS, Kampik A. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 2007;85:119-20. (Pubitemid 46140172)
29. Paccola L, Cost RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME Study). Br J Ophthalmol 2008;92:76-80.
30. Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T, et al. Comparative therapy evaluation of intravitreal bevacizumab and triomcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008;145:854-61.